GB201818576D0 - Arginase 2 polypeptides - Google Patents

Arginase 2 polypeptides

Info

Publication number
GB201818576D0
GB201818576D0 GBGB1818576.9A GB201818576A GB201818576D0 GB 201818576 D0 GB201818576 D0 GB 201818576D0 GB 201818576 A GB201818576 A GB 201818576A GB 201818576 D0 GB201818576 D0 GB 201818576D0
Authority
GB
United Kingdom
Prior art keywords
arginase
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1818576.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IO Biotech ApS
Original Assignee
IO Biotech ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IO Biotech ApS filed Critical IO Biotech ApS
Priority to GBGB1818576.9A priority Critical patent/GB201818576D0/en
Publication of GB201818576D0 publication Critical patent/GB201818576D0/en
Priority to EP19805931.3A priority patent/EP3880225A1/en
Priority to KR1020217017730A priority patent/KR20210093287A/ko
Priority to SG11202104881VA priority patent/SG11202104881VA/en
Priority to JP2021526247A priority patent/JP7611137B2/ja
Priority to PCT/EP2019/081369 priority patent/WO2020099582A1/en
Priority to CA3118794A priority patent/CA3118794A1/en
Priority to CN201980075475.8A priority patent/CN113164545B/zh
Priority to AU2019378076A priority patent/AU2019378076B2/en
Priority to US17/293,325 priority patent/US12234288B2/en
Priority to IL283133A priority patent/IL283133B1/en
Priority to US19/028,166 priority patent/US20250388674A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03001—Arginase (3.5.3.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GBGB1818576.9A 2018-11-14 2018-11-14 Arginase 2 polypeptides Ceased GB201818576D0 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
GBGB1818576.9A GB201818576D0 (en) 2018-11-14 2018-11-14 Arginase 2 polypeptides
US17/293,325 US12234288B2 (en) 2018-11-14 2019-11-14 Immunogenic arginase 2 polypeptides
JP2021526247A JP7611137B2 (ja) 2018-11-14 2019-11-14 免疫原性アルギナーゼ２ポリペプチド
KR1020217017730A KR20210093287A (ko) 2018-11-14 2019-11-14 면역원성 아르기나제 2 폴리펩티드
SG11202104881VA SG11202104881VA (en) 2018-11-14 2019-11-14 Immunogenic arginase 2 polypeptides
EP19805931.3A EP3880225A1 (en) 2018-11-14 2019-11-14 Immunogenic arginase 2 polypeptides
PCT/EP2019/081369 WO2020099582A1 (en) 2018-11-14 2019-11-14 Immunogenic arginase 2 polypeptides
CA3118794A CA3118794A1 (en) 2018-11-14 2019-11-14 Immunogenic arginase 2 polypeptides
CN201980075475.8A CN113164545B (zh) 2018-11-14 2019-11-14 免疫原性精氨酸酶2多肽
AU2019378076A AU2019378076B2 (en) 2018-11-14 2019-11-14 Immunogenic Arginase 2 polypeptides
IL283133A IL283133B1 (en) 2018-11-14 2021-05-12 Immunogenic Arginase 2 proteins
US19/028,166 US20250388674A1 (en) 2018-11-14 2025-01-17 Immunogenic arginase 2 polypeptides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1818576.9A GB201818576D0 (en) 2018-11-14 2018-11-14 Arginase 2 polypeptides

Publications (1)

Publication Number Publication Date
GB201818576D0 true GB201818576D0 (en) 2018-12-26

Family

ID=64739444

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1818576.9A Ceased GB201818576D0 (en) 2018-11-14 2018-11-14 Arginase 2 polypeptides

Country Status (11)

Country Link
US (2) US12234288B2 (https=)
EP (1) EP3880225A1 (https=)
JP (1) JP7611137B2 (https=)
KR (1) KR20210093287A (https=)
CN (1) CN113164545B (https=)
AU (1) AU2019378076B2 (https=)
CA (1) CA3118794A1 (https=)
GB (1) GB201818576D0 (https=)
IL (1) IL283133B1 (https=)
SG (1) SG11202104881VA (https=)
WO (1) WO2020099582A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113164545A (zh) * 2018-11-14 2021-07-23 Io生物技术公司 免疫原性精氨酸酶2多肽

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201912030D0 (en) * 2019-08-21 2019-10-02 Cancer Research Tech Ltd Binding molecules
WO2023161350A1 (en) 2022-02-24 2023-08-31 Io Biotech Aps Nucleotide delivery of cancer therapy
JP2025508840A (ja) 2022-02-24 2025-04-10 アイオー バイオテック エーピーエス アルギナーゼ２ワクチン

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US5780286A (en) * 1996-03-14 1998-07-14 Smithkline Beecham Corporation Arginase II
CA2296792A1 (en) * 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
US20070014801A1 (en) * 2001-01-24 2007-01-18 Gish Kurt C Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
AU2002215345A1 (en) * 2000-10-13 2002-04-22 Eos Biotechnology, Inc. Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
PT3778885T (pt) * 2008-10-31 2023-05-31 Aerase Inc Composições de arginases humanas modificadas e métodos para o tratamento do cancro
CA2988388C (en) * 2015-04-23 2022-11-22 Nantomics, Llc Cancer neoepitopes
DK3423087T3 (da) * 2016-03-04 2023-12-18 Io Biotech Aps Kombinationsterapi mod cancer
GB2568000A (en) * 2016-08-08 2019-05-01 Aerase Inc Compositions and methods for treating cancer with arginine depletion and immuno oncology agents
JP7211938B2 (ja) * 2016-10-07 2023-01-24 アイオー バイオテック エーピーエス 免疫原性アルギナーゼペプチド
GB201815549D0 (en) 2018-09-24 2018-11-07 Io Biotech Aps Arginase1 polypeptides
GB201818576D0 (en) * 2018-11-14 2018-12-26 Io Biotech Aps Arginase 2 polypeptides

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113164545A (zh) * 2018-11-14 2021-07-23 Io生物技术公司 免疫原性精氨酸酶2多肽
CN113164545B (zh) * 2018-11-14 2026-04-10 Io生物技术公司 免疫原性精氨酸酶2多肽

Also Published As

Publication number Publication date
CN113164545A (zh) 2021-07-23
AU2019378076B2 (en) 2025-08-07
IL283133A (en) 2021-06-30
JP7611137B2 (ja) 2025-01-09
US12234288B2 (en) 2025-02-25
CN113164545B (zh) 2026-04-10
AU2019378076A1 (en) 2021-05-27
CA3118794A1 (en) 2020-05-22
SG11202104881VA (en) 2021-06-29
KR20210093287A (ko) 2021-07-27
EP3880225A1 (en) 2021-09-22
JP2022507373A (ja) 2022-01-18
WO2020099582A1 (en) 2020-05-22
IL283133B1 (en) 2026-03-01
US20210403566A1 (en) 2021-12-30
US20250388674A1 (en) 2025-12-25

Similar Documents

Publication Publication Date Title
IL289122A (en) polypeptides
IL289119A (en) polypeptides
IL283133A (en) Immunogenic arginase 2 proteins
GB201820556D0 (en) Novel polypeptides
SG11202102378WA (en) Arginase1 polypeptides
GB201911708D0 (en) Polypeptides
GB201811755D0 (en) Polypeptides
GB201814309D0 (en) 25164 test
GB201807890D0 (en) Polypeptides
GB201807895D0 (en) Polypeptides
GB201807893D0 (en) Polypeptides
GB201808284D0 (en) Test 4
GB201805873D0 (en) Novel polypeptides
GB201807080D0 (en) Concept 54
GB201807108D0 (en) Concept 156
GB201807136D0 (en) Concept 53
GB201807134D0 (en) Concept 35
GB201807133D0 (en) Concept 51
GB201807078D0 (en) Concept 169
GB201807079D0 (en) Concept 168
GB201807132D0 (en) Concept 44
GB201807081D0 (en) Concept 23
GB201807082D0 (en) Concept 32
GB201807083D0 (en) Concept 29
GB201807084D0 (en) Concept 33

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)